Association of immune-related adverse events and outcomes in kidney cancer

Previous studies have shown that cancer patients who experience immune-related side effects (immune-related adverse events) when treated with immunotherapy may have a better response to treatment. This study looks at this effect in patients with metastatic renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (immunotherapy). In the study, 43 patients with metastatic RCC were […]

read more

Patients with autoimmune disorders have more immune-related side effects to immunotherapy

A study published in The Oncologist recently shows that patients with pre-existing autoimmune disorders are at an increased risk of developing immune-related side effects when treated with immunotherapy. This is regardless of tumour type, gender and general wellbeing. However, these patients can still be treated with immunotherapy. The study included 751 patients with four different […]

read more

ASCO GU 2021: Immunotherapy for untreated non-clear cell kidney cancer

Results of a retrospective study presented during the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) looked at the effect of immune checkpoint inhibitors (immunotherapy, e.g. nivolumab, ipilimumab, pembrolizumab) on the survival of patients with metastatic non-clear cell renal cell carcinoma (RCC) compared to targeted therapy with vascular endothelial growth factor (VEGF) […]

read more

Effect of antibiotics on outcomes with systemic treatments for metastatic kidney cancer

The microbes in the gut (the gut microbiome) are a key part of our immune system. The use of antibiotics disrupts the gut microbiome and has been shown to make people susceptible to various illnesses. In this study, researchers investigated how antibiotics may influence response to treatment and clinical outcomes in people with metastatic renal […]

read more

Age-based outcomes in kidney cancer patients treated with first-line targeted therapy or immunotherapy

This study compared disease outcomes, treatments, and dose reductions in patients undergoing first-line treatment with targeted therapy or immune checkpoint inhibitor therapy (immunotherapy) for metastatic renal cell carcinoma (RCC) according to age. Patients aged ≥75 years had a longer time from diagnosis to start of treatment with targeted therapy than those aged <65 years and […]

read more

Checkpoint inhibitor re-challenge after immune-related adverse events

Immunotherapy has revolutionised treatment in many cancers, including renal cell carcinoma (RCC). This study looked at giving patients immunotherapy after they had experienced an immune-related adverse event. With nivolumab in RCC, the probability of having a severe or life-threatening adverse event is very low. Nivolumab alone is very well tolerated. However, with the ipilimumab plus […]

read more

Nephritis as a potential predictor of response to immune checkpoint inhibitors in kidney cancer

This study, to be published in Journal for Immunotherapy of Cancer, looks at the immune-related adverse event, acute interstitial nephritis (inflammation of the kidney tissues), as a biomarker for response to immune checkpoint inhibitors. Using a database, the researchers identified 177 patients with metastatic renal cell carcinoma (RCC) who received at least one dose of […]

read more

γ-Glutamyltransferase as a biomarker in patients on nivolumab for metastatic kidney cacner

A protein called γ-glutamyltransferase can predict survival in patients with local and metastatic renal cell carcinoma (RCC); however, in patients treated with immune checkpoint inhibitors, such as nivolumab, this predictive role is unknown. A study to be published in the International Journal of Clinical Oncology aimed to investigate the role of γ-glutamyltransferase as a predictive […]

read more

Safety and efficacy of tivozanib–nivolumab combination in patients with metastatic kidney cancer

In this phase 1b/2 study the researchers looked at a combination of tivozanib and nivolumab in 25 patients with metastatic renal cell carcinoma (RCC). Tivozanib is a targeted therapy called a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) that blocks the growth of blood vessels to the tumour, while nivolumab is an immune […]

read more

Immune-related adverse events from cabozantinib plus atezolizumab as first-line treatment for advanced kidney cancer

The COSMIC-021 clinical trial investigated a combination of cabozantinib and atezolizumab in untreated clear-cell renal cell carcinoma (RCC). In this video interview, Dr Monty Pal from the City of Hope Hospital in California discusses the side effects from this combination of drugs. There were two groups of patients; one on 60 mg of cabozantinib plus […]

read more
Showing 1 to 10 of 182 results
  TOP